Skip to main content
Alnylam Pharmaceuticals, Inc. (LON:0HD2)
London flag London · Delayed Price · Currency is GBP · Price in USD
262.11
+2.19 (0.84%)
At close: May 12, 2025

Revenue by Product

Fiscal year is January - December.
Fiscal Year
 TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
 Mar '25 Dec '24 Dec '23 Dec '22 Dec '21
Other - Collaboration Revenue (Pre-FY2023)
-
Log In
Log In
Log In
Log In
Other - Collaboration Revenue (Pre-FY2023) Growth
-
Log In
Log In
Log In
Log In
Total Collaboration
490.86M
Log In
Log In
Log In
Log In
Total Collaboration Growth
-21.87%
Log In
Log In
Log In
Log In
Novartis AG - Collaboration
-
Log In
Log In
Log In
Log In
Novartis AG - Collaboration Growth
-
Log In
Log In
Log In
Log In
Vir Biotechnology - Collaboration
-
Log In
Log In
Log In
Log In
Vir Biotechnology - Collaboration Growth
-
Log In
Log In
Log In
Log In
Other - Collaboration Revenue (Post-FY2022)
36.68M
Log In
Log In
Log In
Log In
Other - Collaboration Revenue (Post-FY2022) Growth
64.94%
Log In
Log In
Log In
Log In
ONPATTRO
233.13M
Log In
Log In
Log In
Log In
ONPATTRO Growth
-27.44%
Log In
Log In
Log In
Log In
Total Product
1.75B
Log In
Log In
Log In
Log In
Total Product Growth
31.52%
Log In
Log In
Log In
Log In
GIVLAARI
264.78M
Log In
Log In
Log In
Log In
GIVLAARI Growth
15.42%
Log In
Log In
Log In
Log In
Regeneron Pharmaceuticals - Collaboration
327.07M
Log In
Log In
Log In
Log In
Regeneron Pharmaceuticals - Collaboration Growth
204.99%
Log In
Log In
Log In
Log In
OXLUMO
166.49M
Log In
Log In
Log In
Log In
OXLUMO Growth
29.74%
Log In
Log In
Log In
Log In
Royalty
107.64M
Log In
Log In
Log In
Log In
Royalty Growth
140.50%
Log In
Log In
Log In
Log In
AMVUTTRA
1.09B
Log In
Log In
Log In
Log In
AMVUTTRA Growth
66.62%
Log In
Log In
Log In
Log In
Roche - Collaboration
61.87M
Log In
Log In
Log In
Log In
Roche - Collaboration Growth
-
Log In
Log In
Log In
Log In